

Manuela Funke-Chambour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8816913/publications.pdf>

Version: 2024-02-01

35
papers

968
citations

623188

14
h-index

476904

29
g-index

42
all docs

42
docs citations

42
times ranked

1657
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. <i>European Respiratory Journal</i> , 2021, 57, 2003690.	3.1	291
2	Medium throughput breathing human primary cell alveolus-on-chip model. <i>Scientific Reports</i> , 2018, 8, 14359.	1.6	132
3	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. <i>European Respiratory Journal</i> , 2020, 55, 1901760.	3.1	61
4	Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis – a potential biomarker role for LysoPC. <i>Respiratory Research</i> , 2018, 19, 7.	1.4	58
5	Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID. <i>Respiration</i> , 2021, 100, 826-841.	1.2	41
6	Surfactant replacement therapy reduces acute lung injury and collapse induration-related lung remodeling in the bleomycin model. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 313, L313-L327.	1.3	39
7	Human microvasculature-on-a-chip: anti-neovasculogenetic effect of nintedanib in vitro. <i>Angiogenesis</i> , 2018, 21, 861-871.	3.7	36
8	Human-Based Advanced in vitro Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 644678.	1.2	31
9	Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment. <i>Respiration</i> , 2017, 93, 363-378.	1.2	26
10	Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls. <i>Respiratory Research</i> , 2020, 21, 25.	1.4	26
11	Lysophosphatidic Acid Signaling through the Lysophosphatidic Acid-1 Receptor Is Required for Alveolarization. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 105-116.	1.4	24
12	Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease. <i>Chest</i> , 2021, 160, 994-1005.	0.4	20
13	Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Crossover Trial. <i>Annals of the American Thoracic Society</i> , 2021, 18, 2018-2026.	1.5	19
14	Idiopathic pulmonary fibrosis: the turning point is now!. <i>Swiss Medical Weekly</i> , 2015, 145, w14139.	0.8	18
15	Imaging in the aftermath of COVID-19: what to expect. <i>European Radiology</i> , 2021, 31, 4390-4392.	2.3	17
16	Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis. <i>Respirology</i> , 2018, 23, 764-770.	1.3	14
17	Novel insights in cough and breathing patterns of patients with idiopathic pulmonary fibrosis performing repeated 24-hour-respiratory polygraphies. <i>Respiratory Research</i> , 2017, 18, 190.	1.4	13
18	Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000827.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Frailty assessment for COVID-19 follow-up: a prospective cohort study. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001227.	1.2	12
20	MRI Shows Lung Perfusion Changes after Vaping and Smoking. <i>Radiology</i> , 2022, 304, 195-204.	3.6	9
21	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. <i>Frontiers in Medicine</i> , 2021, 8, 699644.	1.2	8
22	Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre. <i>Swiss Medical Weekly</i> , 2018, 148, w14577.	0.8	8
23	Fatigue in Post-COVID-19 Syndrome: Clinical Phenomenology, Comorbidities and Association With Initial Course of COVID-19. <i>Journal of Central Nervous System Disease</i> , 2022, 14, 117957352211027.	0.7	6
24	Perioperative Lung Function Monitoring for Anatomic Lung Resections. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1725-1732.	0.7	5
25	Multidisciplinary discussion for diagnosis of interstitial lung disease in real life. <i>Swiss Medical Weekly</i> , 2016, 146, w14318.	0.8	5
26	New radiological diagnostic criteria: impact on idiopathic pulmonary fibrosis diagnosis. <i>European Respiratory Journal</i> , 2019, 54, 1900905.	3.1	4
27	Performance of a diagnostic algorithm for fibrotic hypersensitivity pneumonitis. A caseâ€“control study. <i>Respiratory Research</i> , 2021, 22, 120.	1.4	4
28	Pulmonary hypertension associated with chronic lung diseases. <i>Swiss Medical Weekly</i> , 2016, 146, w14363.	0.8	4
29	Evaluation of a Novel Ear Pulse Oximeter: Towards Automated Oxygen Titration in Eyeglass Frames. <i>Sensors</i> , 2020, 20, 3301.	2.1	2
30	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. <i>European Respiratory Journal</i> , 2021, 57, 2004219.	3.1	2
31	Registries for Idiopathic Pulmonary Fibrosis: When Is It Time to Go Global?. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1378-1379.	1.5	2
32	The Octopus Signâ€“A New HRCT Sign in Pulmonary Langerhans Cell Histiocytosis. <i>Diagnostics</i> , 2022, 12, 937.	1.3	2
33	Influence of ventilation inhomogeneity on diffusing capacity of carbon monoxide in smokers without COPD. <i>ERJ Open Research</i> , 2021, 7, 00706-2020.	1.1	1
34	P054 < break /> Exhaled breath condensate- a potential biomarker tool for patients with idiopathic pulmonary fibrosis?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, , .	0.2	0
35	Antifibrotics: Shrinking the Box of Therapeutic Uncertainty. <i>Respiration</i> , 2019, 97, 202-204.	1.2	0